ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

ANALYSIS OF MEDICATION OF ALZHEIMER’S DISEASE AMONG LOCAL POPULATION OF PAKISTAN

Rabia Islam, Sania Bano, Muhammad Amjad

Introduction: Alzheimer’s disease (AD) is the most common form of dementia accounting for 60–80% of dementia diagnosis and affects nearly 50 million people worldwide. Two classes of medications are FDA approved for the treatment of Alzheimer's disease (AD), acetylcholinesterase inhibitors and an NMDA receptor antagonist. Aims and objectives: The basic aim of the study is to analyze the medication of Alzheimer’s disease commonly used in Pakistan. Methodology of the study: This cross sectional study was conducted in Medicare hospital, Faisalabad during February 2019 to August 2019. We collect the data from doctors and patients both because we want to find the therapeutics of AD in local population of Pakistan. Results: To provide early and accurate diagnosis of AD, extensive efforts have been made into developing sophisticated methods to assess pathology in the living human brain. However, to date, no test or combination of tests that could accurately diagnose AD is available for broad clinical use outside of AD research centers. Conclusion: It is concluded that there are no clear and perfect medication for AD. The current diseased approach for AD consists of optimizing modifiable risk factors to reduce and delay symptom onset as well as symptomatic treatment after disease onset.

FULL TEXT